Singular Genomics introduced Direct-Seq technology for in situ sequencing of FFPE samples on its G4X platform and announced the SPOT-Met colorectal cancer study at AGBT 2026, analyzing 1,000 tumors using spatial multiomics.
The system features advanced thermal technology and modular block configurations to support complex molecular biology protocols.
TCM Biotech has received FDA Breakthrough Device Designation for CatCHimera, a liquid biopsy platform for monitoring minimal residual disease in hepatocellular carcinoma using HBV–host genome integration biomarkers.
CellCarta has secured exclusive global rights to deploy Biofidelity’s Aspyre Lung assay in lung cancer clinical trials, streamlining genomic testing for trial sponsors and reducing reliance on multiple vendors.
Read More
A $4 million financing round will support development of a liquid specimen biorepository and expand biopsy catchment pilot programs at medical institutions across the US.
Read More
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
Read More
Presentations at the upcoming annual meeting will focus on AI-based analysis, biomarker prevalence, and therapy development.
Read More
The recommendations focus on using next-generation sequencing to evaluate off-target editing risks and chromosomal integrity.
Read More
Biodesix will present seven abstracts—including two oral sessions—at AACR 2026, highlighting advances in automated myeloid testing, liquid biopsy, and NGS-based cancer monitoring platforms.
Read More
A peer-reviewed study suggests molecular signatures can be identified without invasive uterine sampling using whole-transcriptome sequencing and machine learning.
Read More
The BiliSeq molecular test detected bile duct cancer in 82% of cases—compared to 44% with standard pathology—according to a six-year, multi-institutional study.
Read More
The companion diagnostic can now help identify patients with esophageal or gastroesophageal junction carcinoma who may be eligible for pembrolizumab treatment.
Read More
A retrospective study in Lymphatics reports that CSF liquid biopsy testing delivered clinical impact in 82% of CNS lymphoma cases, resolving diagnoses and informing treatment when standard methods were inconclusive.
Read More
New additions to the COMET suite aim to improve flexibility and sensitivity in multiplex tissue analysis for research and preclinical development.
Read More
Powered by anchored multiplex PCR chemistry, the in vitro diagnostic offerings target fusion and variant detection for molecular pathology laboratories.
Read More
Researchers found that circulating tumor DNA testing could identify which older patients with estrogen receptor–positive breast cancer are less likely to respond to hormone therapy alone.
Read More
Cirena has licensed a University of Colorado Boulder RNA synthesis technology, enabling scalable production of high-purity, 100–400 nt RNA constructs for CRISPR, functional genomics, and RNA therapeutics research.
Read More
Baylor Genetics has added optical genome mapping and long-read sequencing to its whole genome sequencing test, expanding STR analysis, enabling FMR1 methylation detection, and improving structural variant interpretation.
Read More